Tripos Joins SciTegic's ISV Program; Companies to Integrate Tripos' Discovery Informatics Software and SciTegic's Pipeline Pilot Application.

SAN DIEGO & ST. LOUIS -- SciTegic, the leader in data pipelining and workflow tools, and Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry and informatics products and services, announced today that Tripos has joined SciTegic's independent software vendor (ISV) partner program to provide software compatibility between their product lines. Joint customers may now choose to access Tripos' discovery informatics technology from within SciTegic's Pipeline Pilot framework, leading to more efficient and repeatable discovery processes.

SciTegic pioneered the data pipelining technology for processing drug discovery data that is now employed by more than 150 pharmaceutical research organizations worldwide. Tripos is one of 12 ISV partners and, through the agreement, will receive training, consulting and support from SciTegic to achieve high-quality integration.

"Many of our customers already use Tripos' software and find it to be critical to their discovery research processes," said Mathew Hahn, Ph.D., vice president and general manager of SciTegic. "Through this partnership, our joint users will employ Tripos technologies in the workflow-centric Pipeline Pilot environment to solve more complex problems, and to reach a broader audience of users through the flexible deployment of validated processing routines."

Earlier this month, Tripos announced plans to provide its customers with more flexible options to develop, deploy and access core discovery informatics applications by adopting Web services and related service-oriented informatics (SOI) technologies. The agreement with SciTegic is a vital part of this strategy, providing customers with the ability to use innovative Tripos products such as UNITY(R), Concord(R) and LITHIUM(R) when creating and executing distributed discovery protocols using Pipeline Pilot.

"Workflow applications such as Pipeline Pilot have quickly become indispensable drug discovery informatics tools," said Bryan Koontz, senior vice president and general manager of Discovery Informatics at Tripos. "SciTegic created this software category, and we are pleased to already be working closely with the company's product development staff to provide our customers with integrated solutions to improve the performance and overall impact of Tripos software."

Tripos plans to provide a standard set of discovery informatics components for Pipeline Pilot as part of its forthcoming Informatics Web Services Toolkit, scheduled to ship later this year. A Pipeline Pilot component for Concord, the industry's leading 3-D structure generation application, is available now for download from SciTegic's support Web site.

About SciTegic

SciTegic, a wholly owned subsidiary of Accelrys, Inc. (NASDAQ:ACCL), develops and markets informatics software for various industries, including the pharmaceutical and biotechnology industries. The company has pioneered a technology approach called "Data Pipelining" to process drug discovery data with unprecedented flexibility. This methodology has established its utility by accelerating informatics research for thousands of users at over one hundred customer sites worldwide. Further information about SciTegic is available at: http://www.scitegic.com.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Within Tripos' Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos' Discovery Research (DR) business, Tripos' medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com.

This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as "expects," "anticipates," "projects," "estimates," "intends," "plans," "believes," variations of such words and similar expressions are intended to identify such forward-looking statements. Such statements include the successful integration of Tripos products within SciTegic's Pipeline Pilot and the adoption of these tools by customers. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. Accelrys and Tripos have identified certain factors that could cause actual results to differ materially from the forward-looking statements in their Annual Report on Form 10-K, their Quarterly Reports on Form 10-Q, and their Current Reports on Form 8-K. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, Accelrys and Tripos do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

Tripos and the Tripos logo are registered trademarks of Tripos, Inc., and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners.